Lymphocyte predominant Hodgkin’s disease: Pathology and clinical implication
Tài liệu tham khảo
Lukes, 1966, The pathology and nomenclature of Hodgkin’s disease, Cancer Res, 26, 1063
Lukes, 1966, Natural history of Hodgkin’s disease as related to its pathologic picture, Cancer, 19, 317, 10.1002/1097-0142(196603)19:3<317::AID-CNCR2820190304>3.0.CO;2-O
Poppema, 1992, Lymphocyte-predominance Hodgkin’s disease, Sem Diagn Pathol, 9, 257
Harris, 1994, A Revised European–American Classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group, Blood, 84, 1361, 10.1182/blood.V84.5.1361.1361
Westling, 1965, Studies of the prognosis in Hodgkin’s disease, Acta Radiol, 245, 5
Rosenthal, 1936, Significance of tissue lymphocytes in the prognosis of lymphogranulomatosis, Arch Pathol, 21, 628
Jackson, 1947
Keller, 1968, Correlation of histopathology with other prognostic indicators in Hodgkin’s disease, Cancer, 22, 487, 10.1002/1097-0142(196809)22:3<487::AID-CNCR2820220302>3.0.CO;2-F
Gough, 1970, Hodgkin’s disease: A correlation of histopathology with survival, Int J Cancer, 5, 273, 10.1002/ijc.2910050216
Peters, 1950, A study of survivals in Hodgkin’s disease treated radiologically, Am J Roentgenol, 63, 299
Culine, 1989, Relationship of histological subtypes to prognosis in early stage Hodgkin’s disease: A review of 312 cases in a controlled clinical trial, Eur J Cancer Clin Oncol, 25, 551, 10.1016/0277-5379(89)90269-1
Shankar, 1997, Does histology influence outcome in childhood Hodgkin’s disease? Results from the United Kingdom Children’s Cancer Study Group, J Clin Oncol, 15, 2262, 10.1200/JCO.1997.15.7.2622
Sextro, 1996, for the European Task Force on Lymphoma.. Lymphocyte predominance Hodgkin’s disease – a workshop report, Ann Oncol, 7, 61, 10.1093/annonc/7.suppl_4.S61
Hansmann, 1984, Clinical features of nodular paragranuloma (Hodgkin’s disease, lymphocyte predominance type, nodular), J Cancer Res Clin Oncol, 108, 321, 10.1007/BF00390466
Borg-Grech, 1989, A comparative study of the nodular and diffuse variants of lymphocyte-predominant Hodgkin’s disease, J Clin Oncol, 7, 1303, 10.1200/JCO.1989.7.9.1303
von Wasielewski, 1997, Lymphocyte predominant Hodgkin’s disease. An immunohistochemical analysis of 208 reviewed Hodgkin’s disease cases from the German Hodgkin Study Group, Am J Pathol, 150, 793
Bodis, 1997, Clinical presentation and outcome in lymphocyte-predominant Hodgkin’s disease, J Clin Oncol, 15, 3060, 10.1200/JCO.1997.15.9.3060
Regula, 1988, Nodular and diffuse types of lymphocyte predominance Hodgkin’s disease, N Engl J Med, 318, 214, 10.1056/NEJM198801283180404
Orlandi, 1997, Nodular lymphocyte predominance Hodgkin’s disease: Long-term observation reveals a continuous pattern of recurrence, Leuk Lymph, 26, 359, 10.3109/10428199709051786
Crennan, 1995, Lymphocyte predominant Hodgkin’s disease: A clinicopathologic comparative study study of histologic and immunophenotypic subtypes, Int J Radiat Oncol Biol Phys, 31, 337, 10.1016/0360-3016(94)E0136-8
Miettinen, 1983, Hodgkin’s disease, lymphocyte predominance nodular. Increased risk of subsequent non-Hodgkin’s lymphoma, Cancer, 51, 2293, 10.1002/1097-0142(19830615)51:12<2293::AID-CNCR2820511221>3.0.CO;2-X
Mauch, 1993, Patterns of presentation of Hodgkin’s disease. Implications for etiology and prognosis, Cancer, 71, 2062, 10.1002/1097-0142(19930315)71:6<2062::AID-CNCR2820710622>3.0.CO;2-0
Dawson, 1961, A clinicopathological study of benign Hodgkin’s disease, J Clin Pathol, 14, 219, 10.1136/jcp.14.3.219
Henry-Amar, 1992, Second cancer after the treatment of Hodgkin’s disease: A report from the International Database on Hodgkin’s disease, Ann Oncol, 3, 117, 10.1093/annonc/3.suppl_4.S117
Soubeyran, 1996, Is there any place for a wait-and-see policy in stage 1.0 follicular lymphoma. A study of 43 consecutive patients in a single center, Ann Oncol, 7, 713, 10.1093/oxfordjournals.annonc.a010720
Maloney, 1997, IDEC-C2B8 Results of a phase I multiple dose trial in patients with relapsed non-Hodgkin’s Lymphoma, J Clin Oncol, 15, 3266, 10.1200/JCO.1997.15.10.3266
Coiffier, 1997, A multicenter, randomised phase II study of Rituximab (chimeric anti-CD20 mAB) at two dosages in patients with relapsed or refractory intermediate or high-grade NHL (IHG-NHL) or in elderly patients in first-line therapy, Blood, 90, 510a